Immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to Vietnamese children at 18 months of age

Rachel A. Higgins, Beth Temple, Vo Thi Trang Dai, Thanh V. Phan, Nguyen Trong Toan, Leena Spry, Zheng Quan Toh, Monica L. Nation, Belinda D. Ortika, Doan Y. Uyen, Yin Bun Cheung, Cattram D. Nguyen, Kathryn Bright, Jason Hinds, Anne Balloch, Heidi Smith-Vaughan, Tran Ngoc Huu, Kim Mulholland, Catherine Satzke, Paul V. Licciardi

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)
84 Downloads (Pure)

Abstract

Background: This study investigated the immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to 18-month-old Vietnamese children. This information is important for countries considering catch-up vaccination during PCV introduction and in the context of vaccination during humanitarian crises. Methods: Two groups of PCV-naïve children within the Vietnam Pneumococcal Project received PCV10 (n=197) or no PCV (unvaccinated; n=199) at 18 months of age. Blood samples were collected at 18, 19, and 24 months of age, and nasopharyngeal swabs at 18 and 24 months of age. Immunogenicity was assessed by measuring serotype-specific IgG, opsonophagocytosis (OPA) and memory B cells (Bmem). Pneumococci were detected and quantified using real-time PCR and serotyped by microarray. Findings: At 19 months of age, IgG and OPA responses were higher in the PCV10 group compared with the unvaccinated group for all PCV10 serotypes and cross-reactive serotypes 6A and 19A. This was sustained out to 24 months of age, at which point PCV10-type carriage was 60% lower in the PCV10 group than the unvaccinated group. Bmem levels increased between 18 and 24 months of age in the vaccinated group. Interpretation: We demonstrate strong protective immune responses in vaccinees following a single dose of PCV10 at 18 months of age, and a potential impact on herd protection through a substantial reduction in vaccine-type carriage. A single dose of PCV10 in the second year of life could be considered as part of catch-up campaigns or in humanitarian crises to protect children at high-risk of pneumococcal disease.

Original languageEnglish
Article number100273
Pages (from-to)1-11
Number of pages11
JournalThe Lancet Regional Health - Western Pacific
Volume16
DOIs
Publication statusPublished - Nov 2021

Bibliographical note

Funding Information:
This work was supported by the National Health and Medical Research Council (NHMRC) of Australia (grant number 566792) and the Bill & Melinda Gates Foundation (grant number OPP1116833). PVL is a recipient of a NHMRC Career Development Fellowship (1146198). CS was the recipient of a NHMRC Career Development Fellowship (1087957) and a Veski Inspiring Women Fellowship. GlaxoSmithKline Biologicals SA donated the doses of PCV10 and provided support for the opsonophagocytosis testing. We also acknowledge the Victorian Government's Operational Infrastructure Support Program.

Fingerprint

Dive into the research topics of 'Immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to Vietnamese children at 18 months of age'. Together they form a unique fingerprint.

Cite this